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Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare and the majority of patients present
with advanced disease. Such patients have limited treatment options. We conducted a systematic review
of published clinical trials of non-surgical interventions in pNET, to understand the efﬁcacy, safety and
health related quality of life (HRQoL) outcomes from the current evidence base.
Methods: Electronic databases and manual bibliographic searches were conducted to identify relevant
studies. Data were extracted by two independent reviewers.
Results: Forty seven clinical studies met the predeﬁned inclusion criteria. The following interventions
were included: targeted therapies (two RCTs and six single-arm studies), chemotherapy (two RCTs,
one prospective nonrandomised, comparative study and 14 single-arm studies);somatostatin analogues
(SSA) and radiolabeled SSA therapies (nine single-arm studies), liver-directed therapies (six single-arm
studies), mixed treatment regimens (one RCT, four single-arm studies) and other interventions such as
interferon and recombinant human endostatin (one single-arm study for each). The paucity of RCT data
and lack of consistency in reporting validated study outcomes and differing patient inclusion criteria
between studies made it difﬁcult to compare the relative efﬁcacy of therapies.
Discussion: The majority of published studies assessing treatment regimens for the management of pNET
are single arm, non-randomised studies, often enrolling a small number of patients and not reporting
clinically meaningful outcomes. However data from recently conducted studies assessing targeted ther-
apies indicate that it is possible to conduct adequately powered RCTs reporting standardised oncological
endpoints in this rare cancer. Further, similarly robust studies should be conducted to deﬁne the optimal
treatment algorithm.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Pancreatic neuroendocrine tumours (pNETs) are rare. World-
wide, the annual incidence of pNET is estimated to range from0.2 to 0.4 per 100,000 population, although due to the relatively
indolent nature of these tumours the true prevalence may be much
higher [1–3]. At presentation, 65% of patients have unresectable or
metastatic disease. The 5-year survival rate of patients with meta-
static disease is 30–40% and has not changed signiﬁcantly over the
last 30 years [4].
Clinically, pNETs are divided into two groups: functional
(10–30%) or non-functional (70–90%). Functional pNETs secrete
biologically active peptides, or hormones producing one of nine
recognised speciﬁc hormonal syndromes. These tumours are
associated with a reduced quality of life (QoL) in patients [5]. The
hormones secreted by functional tumours include gastrin, insulin,
glucagon, somatostatin, vasoactive intestinal polypeptide (VIP),
growth hormone-releasing factor and adrenocorticotrophic
hormone [5]. The hormonal syndromes are associated with diverse
clinical features with regard to both metastatic potential and
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noma will develop metastases, compared with 50% of those with
somatostatinoma and up to 70% of patients with VIPoma [6].
Surgery,where possible, is considered the ﬁrst-line treatment for
pNET patients. Due to the presence of distant metastatic disease or
local extension of the tumour, surgery is often non-curative, but
even in advanced cases surgical debulking of disease can reduce
symptoms related to tumour burden and hormone production [7].
For patients who are not candidates for surgery, the choice of
treatment depends on the stage of the disease, symptoms and
histological features of the tumour [8]. Treatment options include
SSA and liver-directed therapies (for example, chemoembolisation,
radioembolisation, arterial embolisation and radiofrequency abla-
tion, which are palliative options for liver-dominant disease)
[6,7,9–11]. In clinical practice, systemic chemotherapy is commonly
used in the treatment of pNET, but with modest efﬁcacy (responses
are rarelycomplete) andtheattendant toxicityproﬁles. Suchchemo-
therapy agents include streptozocin, doxorubicin, 5-ﬂuorouracil,
dacarbazine, capecitabine and temozolomide [6,7,9,12].
There have been limited developments in the management of
advanced pNET over the last two decades [13,14]. However, an im-
proved understanding of the molecular mechanisms underlying
pNET has led to more recent treatment options that include agents
directed at inhibiting growth factors or their receptors that are pro-
duced by these tumours [15,16]. Several of these agents are still
investigational and to date, only the tyrosine kinase inhibitor sun-
itinib and the mTOR inhibitor everolimus have been licensed by
the European Medicines Agency and the FDA for the treatment of
unresectable or metastatic, well-differentiated pNETs with disease
progression in adults.
A number of reviews of treatments speciﬁcally for pNET have
been previously published [7,15,17], as well as reviews ofTable 1
Inclusion and exclusion criteria.
Criterion Included
Population  Age: P18 years
 Race: any
 Qualifying disease: pancreatic neuroendocrine tumours (pN
 No restriction on previous treatment/surgery (ie treatment
Perspective of
study
 Prospective (concurrent)
 Comparative
 Non-comparative
Study
characteristics
RCTs: parallel/Cross-over design (with adequate wash-out perio
Non-RCTs: cohort/case series
Language  Any
Trial length  All study durations
Sample size  P10 pNET patients
Interventions/
treatments
 Systemic chemotherapy
 Targeted therapies (including everolimus, bevacizumab, sora
 Somatostatin analogue
 Interferon/Biotherapy
 Radionuclide therapy, including peptide receptor radionucli
 Radiofrequency ablation
 Chemo-embolisation
 Hepatic artery embolisation (HAE) with/without chemother
 Combination regimens.
 No restriction on dose, formulation, or mode of delivery
Control
intervention/
treatments
 Any of the interventions listed abovePlacebo/usual careNo tre
Included trial
outcomes
Efﬁcacy, including but not restricted to overall survival, progress
response rate (PR + SD), Time to progression (TTP)/duration of r
Safety, including withdrawals due to:
 Any reason
 Lack of efﬁcacy
 Adverse events
 Health-related quality of life
AE, adverse event; PR, partial response; RCT, randomised controlled trial; SD, stable dis
 Studies enrolling patients with neuroendocrine tumours of any aetiology (including pa
for the pNET subset of patients.treatments for all NETs [12,18–20]. Several evidence-based guide-
lines on the management of pNET are available which include rec-
ommendations for the treatment of pNET (e.g. guidelines from the
UK and Ireland Neuroendocrine Tumour Society (UKINETS) [6], the
National Comprehensive Cancer Network (NCCN) [21] and the
European Neuroendocrine Tumour Society (ENETS) [9].
More recently, key recommendations from the NET Clinical Tri-
als Planning Meeting included the separate examination of carci-
noid tumours and pancreatic NETS in clinical trials and the
avoidance of SSA washout periods when evaluating novel agents
for the control of hormonal syndromes [22]. An update to the UKI-
NETS guidelines covers genetics, diagnosis, imaging, pathology,
treatment, ablation and carcinoid heart disease [23]. Updated con-
sensus guidelines from ENETS are also available [24].
As new targeted therapies emerge andbecomemorewidely used
in the management of pNET, this review was undertaken to under-
stand the current evidence base in terms of efﬁcacy and safety of
non-surgical treatments and to assess the trial methodology sup-
porting the use of chemotherapies and new agents in this setting.Methods
Inclusion criteria
Randomised controlled trials (RCTs), non-RCTs and prospective
single-arm studies were included if they enrolled adult patients
with a conﬁrmed diagnosis of pNET (as deﬁned by recognised clin-
ical guidelines). Studies enrolling patients with NETs of any aetiol-
ogy (including pancreas) were included as long as relevant
efﬁcacy/safety outcomes were reported for the pNET subset of pa-
tients. Only studies with at least 10 pNET patients were included inExcluded
ET)
naïve & refractory patients)
 Age:618 years Non-pancreatic
neuroendocrine tumours
 Retrospective
d between treatments  Case report Case studies with single
patient
-
-
 <10 pNET patients
fenib, sunitinib, geﬁtinib)
de therapy
apy (HACE)
 Surgery
atment -
ion free survival, objective overall
esponse
Studies only reporting symptomatic relief
outcomes for functioning tumours
ease.
ncreas) were be included as long as relevant efﬁcacy/safety outcomes were reported
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felt to be questionable (Table 1).
Identiﬁcation of studies
A systematic review of electronic databases and conference pro-
ceedings was conducted to identify relevant studies. Medline, Em-
base, The Cochrane Library, BIOSIS and ISI Web of Knowledge were
accessed in April 2012. The search combined pNET terms ‘neuroen-
docrine tumor’ and ‘pancreas’ with intervention terms for somato-
statin, chemotherapy and pharmacotherapy agents, interferon,
radionuclide therapies and liver-directed therapies. Conference
proceedings from the American Society of Clinical Oncology
(ASCO), European Neuroendocrine Tumor Society (ENETS) and
the European Society for Medical Oncology (ESMO) were hand-
searched (2006–2012 inclusive).
Identiﬁed studies were independently assessed by two
researchers in order to ascertain whether they met a set of pre-de-
ﬁned inclusion/exclusion criteria for inclusion in the systematic re-
view (Table 1).
Data extraction
A pre-determined data extraction table was designed in an
Excel spreadsheet. The primary efﬁcacy outcomes extractedNo. of records iden
searchi
Duplicates, n= 1,266
No. of records s
abstrac
Included
• 10 pub
• 42 non
Exclusion on basis of title and 
abstract n= 4,933 
Exclusion on basis of 
full publication: n= 129 
No. of full-text articles
(Screened by f
Fig. 1. Study Floincluded overall survival (OS), progression free survival (PFS),
objective overall response rate (ORR), tumour response and time
to progression (TTP)/duration of response. The safety outcomes of
interest included incidence of death, incidence of withdrawal,
and incidence of serious adverse events (AE). Health related quality
of life (HRQoL) data (reported using generic- or disease-speciﬁc
questionnaires) were also extracted.
Quality assessment
Study quality was assessed independently by two reviewers
using the methods recommended in the Cochrane Reviewer’s
handbook [25] for RCTs and the Chambers quality assessment
checklist for single-arm studies [26]. Any differences of opinion
were resolved by discussion and consensus.
Data analysis
As discussed in more detail in the results section, there was
considerable variation between the studies meeting eligibility cri-
teria for inclusion in the review in terms of study design (majority
of studies enrolled single-arm cohorts), reported outcomes and in-
cluded populations. Therefore as a robust meta-analysis comparing
the efﬁcacy and safety of all available treatments was not feasible,
results were summarised qualitatively.tified through database 
ng: N= 6,366 
creened (by title and 
t); N= 5,100 
 publications
lications of 5 RCTs 
-RCTs 
 assessed for eligibility 
ull paper) N= 167 
Handsearching, n= 14
w Diagram.
Table 2
Study characteristics of included studies. Primary outcome shown in bold.
Study reference Study location No. of
patients
Treatment, dose and duration Study population Outcomes reported
Randomised controlled trials (n = 5)
Targeted therapies (n = 2)
Raymond 2011 [33]
Full text
France, UK, Germany,
Belgium, Taiwan,
South Korea,Canada
86 Sunitinib, 37.5 mg/day, continuous daily dosing Well differentiated, pNET; disease
progression < 12 months
PFS, ORR, OS, safety, QoL
85 Placebo, continuous daily dosing
Yao 2011, RADIANT-3 [34]
Full text
USA, Japan, France,
Belgium, Spain,
Netherlands, Italy,
Germany, Sweden
207 Everolimus, 10 mg/day, continuous daily dosing Low-grade or intermediate-grade advanced
pNET and radiological documentation of
disease progression in the 12 months
preceding randomisation
PFS, objective response rate,
duration of response, OS, safety. ,203 Placebo, continuous daily dosing
Chemotherapy (n = 2)
Moertel 1992 [28]
Full text
USA 33 Chlorozotocin IV 150 mg m2 BSA, every 7 weeks Unresectable or metastatic islet-cell
carcinoma
Regression, progression, survival,
safety33 Streptozocin IV 500 mg and Fluorouracil 400 mg per m2
BSA; 5 days, repeated every 6 weeks.
36 Streptozocin IV 500 mg per m2 BSA (5 days)Doxorubicin
50 mg m2 BSA, , day 1 and day 22 of each 6 week cycle
Moertel 1980 [27]
Full text
USA 42 Streptozocin IV 500 mg per m2 BSA/day; 5 days, repeated
every 6 weeks
Unresectable, metastatic islet-cell carcinoma
diagnosed histologically.
ORR, CR, median survival, safety
40 Streptozocin IV 500 mg per m2 BSADoxorubicin 50 mg m2
BSA5 days, repeated every 6 weeks
Mixed treatment (n = 1)
Pavel 2008 [32]
Abstract
NR 8 Streptozotocin 500 mg/m2 + 5-FU 400 mg/m2 IV, day 1-5,
repeated on day 43 for 9 cycles.
Histologically proven, therapy-naïve pNET Response (CR, PR, SD), TTP, safety
8 Octreotide LAR 30 mg IM, monthly
Non-randomised studies (n = 42)
Targeted therapies (n = 6)
Hobday 2007 [38]
Abstract
USA 41 Sorafenib 400 mg BID, continuous daily dosing pNET and carcinoid tumours (n = 50); prior
interferon/ prior or concurrent octreotide
allowed.
Response (PR, MR), PFS, safety
Hobday 2006 [37]
Abstract
USA 39 Geﬁtinib 250 mg BID, continuous daily dosing pNET and carcinoid tumours (n = 57); prior
interferon/ prior or concurrent octreotide
allowed.
PFS, response (PR, MR, SD), safety
Yao 2010 [49]
Full text
International (11
countries)
115 Everolimus 10 mg/day, continuous daily dosing Histologically conﬁrmed, well to moderately
differentiated, advanced pNET
ORR, PFS, duration of response,
OS, safety45 Everolimus 10 mg/day + octreotide LAR (630 mg)
Duran 2006 [51]
Full text
USA, Canada 15 Temsirolimus 25 mg IV/week for 8 weeks Histological/cytological conﬁrmed carcinoid/
pancreatic islet cell tumour with
documented progressive metastatic disease
ORR, SD, duration of SD, TTP, OS,
safety
Kulke 2010 [52]
Abstract
USA 24 Everolimus 5 mg or 10 mg qd with temozolomide 150 mg/
m2 qd given for 7 days, maximum of 6 4-week cycles
Histologic evidence of pNET, not suitable for
curative surgery
Response (PR, SD, PD); safety
Kulke 2008 [36]
Full text
USA 66 Sunitinib, 50 mg/daily for 4 weeks Histologic evidence of PNET; not candidates
for curative surgery
ORR, TTP, OS, safety
Chemotherapy (n = 15)
Bukowski [53]
Full text
USA 44 Good-risk. Chlorozotocin (CTZ) 175 mg/m2 IV day 1 + 5-FU
800 mg/m2/d IV days 1-4; maintenance dose of 100 mg CTZ
and 600 mg of 5-FU. Poor-risk pts given lower
dosage.Maximum of 18 months
Biopsy-proven islet-cell carcinoma, not
amenable to surgery
PR, ORR, OS Safety
Eriksson [54]
Full text
Sweden 25 STZ IV 0.5 g/m2 for 5 days, maintenance of 1 gm/m2 every
third week + doxorubicin 40 mg/m2 every third
week.Median 12 months
Clinically veriﬁed endocrine pancreatic
tumour (benign/ malignant tumours
included)
ORR, OS, safety
19 As above + 5-FU IV 400 mg/m2 every third week.Median
12 months
Fjallskog [55]
Full text
Norway 30 Doxorubicin 30 mg/m2 on day 1 with 1 g Streptozotocin as
bolus injection days 1-5. Median of 13 courses (course every
Histopathologic conﬁrmation of non-
resectable pNET
ORR, PFS, OS, safety
(continued on next page)
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Table 2 (continued)
Study reference Study location No. of
patients
Treatment, dose and duration Study population Outcomes reported
3 weeks) administered
Ramanathan [56]
Full text
USA 50 DTIC 850 mg/m2 IV. At least 2 courses(course every 4 weeks),
continued until progression
Histopathologic conﬁrmation of non-
resectable, malignant islet cell carcinoma
ORR, OS, safety
Bajetta [57]
Full text
Italy 28 5-FU 500 mg/m2, DTIC 200 mg/m2, epiadriamycin 30 mg/m2)
IV on days 1-3. Median: 4 months
NET conﬁrmed by pathology ORR, TTP, OS, safety
Moertel [58]
Full text
USA, Canada, France,
Switzerland
20 Doxorubicin 60 mg/m2 IV, repeated at 3 weeks, 6 weeks and
then every 4 weeks.Until evidence of disease progression or
until a total of doxorubicin dose of 500 mg/m2 had been
administered
Histopathologic conﬁrmation of locally
unresectable or metastatic islet cell
carcinoma
ORR, OS, safety
Bajetta [59]
Full text
Italy 11 Oxaliplatin 130 mg/mq day 1 IV + capecitabine 2000 mg/mq/
die from day 2-15 every 3 weeks.6cycles maximum(each
cycle 3 weeks)
High- low-grade malignant NETs ORR, OS, TTP, safety
Fjallskog [60]
Full text
Sweden 14 Etoposide 100 mg/m2 /day for 3 days + cisplatin 45 mg/m2
per day on days 2 and 3.Cycles repeated every 4 weeks
Histopathologic conﬁrmation of NET ORR, OS, safety
Bajetta [61]
Full text
Italy 15 Fluorouracil 500 mg/m2, DTIC 200 mg/m2 + Epirubicin
30 mg/m2 IV, 3 consecutive days. Cycles repeated every
3 weeks
Histologically proven locally advanced/
metastatic NETs, not amenable to surgery
ORR, PR, CR, safety
Kulke [62]
Full text
USA 29 Temozolomide 150 mg/m2 on days 1 to 7 and days 15 to 21.
Thalidomide 200 mg /day. Cycle repeated every 28 days
Histologically conﬁrmed, locally
unresectable or metastatic neuroendocrine
tumours
ORR, PR, SD, PD, safety
Moertel [63]
Full text
USA NR Etoposide 130 mg/m2/day IV for 3 days, Cisplatin 45 mg/m2
on days 2 and 3. Cycle repeated every 4 weeks
Histologic conﬁrmation of metastatic
neuroendocrine tumour
ORR, SD, OS safety
Rivera [64]
Full text
USA 11 Doxorubicin 40 mg/m2i.v on day 1, Streptozocin 400 mg/
m2i.v and 5-Fluouracil 400 mg/2i.v on days 1 to 5. Cycle
repeated every 4 weeks
Conﬁrmed pNET PR, SD, MR, OS, safety
Sprenger [65]
Abstract
Germany 14 650 mg/m2Dacarbacine once monthly i.v. Metastatic neuroendocrine tumour PR, SD, safety
Strosberg [66]
Abstract
USA 17 Capecitabine 750 mg/m2 twice daily on days 1-14 and
temozolomide 200 mg/m2 daily on days 10-14
Progressive metastatic pNET SD, PR, safety
Brixi-Benmansour [67]
Full text
France 20 FOLFIRI chemotherapy: (irinotecan 180 mg/m2 infusion
combined with simpliﬁedLV5FU2) every 14 days. Cycles
repeated every 14 days using a chemotherapy free-interval
scheme
Metastatic or advanced well-differentiated
pNET and progressive disease.
6 month non-PR, PFS, TTF, OS,
disease duration control, safety,
biological responses at 6, 12, 18,
24 months
SSA/radionuclide therapy (n = 9)
Kwekkeboom [68]
Full text
Netherlands 42 Radiolabeled 177Lu-DOTA,Tyr Octreotate injected IV over 4
hours with saline.
Octreoscan-positive pNET Response (CR, MR, SD, PD), safety
Butturini [69]
Full text
Italy 21 Octreotide 100ug TID s.c. for 2 weeks followed by Octreotide
LAR 20 mg every 28 days.
Octreoscan-positive well-differentiated
nonfunctioning pNET
PFS, SD, safety
Kvols [70]
Full text
USA 22 SSA given s.c. 50ug BID day 1, 100ug BID day 2 then 150ug
TID (n = 12).Dose increased to 250ug, 500ug and 500ug TID
(n = 10).Median 5 months(range 1–15)
Histologically conﬁrmed metastatic islet cell
carcinoma
Response (PR, MR, SD), safety
Forrer [71]
Full text
Switzerland 11 IV 77Lu-DOTATOC 7,400 MB with saline. Histologically conﬁrmed metastatic
neuroendocrine tumour
Response (PR, MR, SD), safety
Frilling [72]
Full text
Switzerland 15 Two applications of 90Lu-DOTATOC (37 to 11 MBq of 111 In-
DOTATOC injected). Each patent underwent at least 2
treatment sessions
Advanced histologically or cytologically
proven progressive metastatic NET.
Response (PR, MR, SD, safety),
Panzuto [73]
Full text
Italy 18 Octreotide LAR 30 mg or Lanreotide SR 60 mg IM injection
every 28 days. Median 18 months (range 6–60)
Well-differentiated endocrine carcinoma Response, OS
Saltz [74]
Full text
USA 13 Octreotide IM 50ug bid increasing to 250ug tid Advanced, incurable NET with conﬁrmed
pathologic status
ORR, OS, safety
Shojamanesh [75]
Full text
USA 15 Short acting Octreotide 200 ug every 12 hours, LR
formulation then used monthly (30 mg IM)
Gastrinoma with histologically proven liver
metastases and disease progression
Response, duration of response,
safety
Waldherr [76]
Full text
Switzerland 13 4 applications of 90Lu-DOTATOC (total 7.4 GBq/m2) Histologically conﬁrmed metastatic
neuroendocrine tumour
Response (SD, PR), OS, safety
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Table 2 (continued)
Study reference Study location No. of
patients
Treatment, dose and duration Study population Outcomes reported
Mixed treatments (n = 4)
Eriksson [77]
Full text
Sweden 92 Chemotherapy: IV Streptozotocin0.5 g/m2 for 5 days
followed by 1 gm/m2 every third week + 5-FU IV 400 mg/m2
for 3 days and then every third week.
Interferon: 5 MU 3 times a week. Octreotide: 100ug bd
Clinically veriﬁed malignant endocrine
pancreatic tumour
Response, duration of response
Yao [78]
Full text
USA 30 Octreotide LAR 30 mg every 28 days + everolimus 5-10 mg/
d. Maximum of 12 cycles
Histologically conﬁrmed metastatic/
unresectablelocoregional LGNETs. Prior
treatment permitted
PFS, OS,ORR, response (PR, PD,
SD), safety
Fjallskog [79]
Full text
Sweden 16 Median dose 9 MU/week interferon + Octreotide (450ug/
day; n = 14) or Lanreotide (3000ug bd; n = 2). Follow up
every 3 months
Histopathologic conﬁrmed pNET Response, duration of response,
safety
Hobday [80]
Abstract
USA 35 Temsirolimus 25 mg IV q week and bevacizumab 10 mg/kg
IV q 2 weeks
Patients with well or moderately
differentiated pNET and PD by RECIST within
seven months of study entry
ORR and 6-month PFS
Liver-directed therapies (n = 6)
Moertel 1994 [81]
Full text
USA 17 Surgical patients: ligation of hepatic artery; other:
catheterisation and embolisation.
Histologically conﬁrmed carcinoid or islet
cell carcinoma with liver metastases
ORR, duration of response; TTP,
median survival; safety
29 Hepatic artery occlusion + chemotherapy
Alternating cycles of doxorubcin and dacarbazine: 5 weeks
later with streptozocin and 5-FU
Rhee 2008 [82]
Full text
USA 11 90Y radioembolization. 3 month follow up Metastatic NET liver disease that had failed
prior treatment
Response (PR, SD, PD); safety
Eriksson 1998 [83]
Full text
Sweden 12 Hepatic artery embolisation Metastatic NET liver disease that had failed
prior treatment
Response, duration of response,
median survival; safety
Ajani 1988 [84]
Full text
USA 20 Hepatic artery embolisation Histologically conﬁrmed islet cell carcinoma Complete/any response; safety
Kim 1999 [85]
Full text
USA 14 Hepatic artery chemo-embolisation. Subsequent treatments
every 8-12 weeks (+ concurrent octreotide)
Histologically conﬁrmed carcinoid/islet cell
carcinoma with liver metastases
Response, median survival,
median duration of response,
safety
Capitanio 2010 [86]
Abstract
Italy 11 Doxorubicin emulsiﬁed in Lipidol, followed by gelatine
sponge particles embolisation
Multifocal metastases with diameter less
than 5 cm, without extrahepatic disease
Safety , long term survival
Interferon (n = 1)
Eriksson 1986 [87]
Full text
Sweden 22 Human leucocyte interferon, 3-6x106 IU Malignant PNET with histopathological
diagnosis
Response (SD, PD); duration of
response; safety
Endostatin (n = 1)
Kulke 2006 [88]
Full text
USA 20 Recombinant human endostatin, 30 mg/m2 bid (28 day
cycle). Median: 6.4 months
Metastatic pNET; prior chemo permitted;
ECOG 0 or 1
Response (PR; CR; SD;
progression); median PFS, OS;
safety
pNET, pancreatic neuroendocrine tumour; BSA, body surface area; CR, complete response; DTIC, dacarbazine; FU, ﬂuorouracil; IM, intramuscular; IV, intravenous; ORR, objective response rate; OS, overall survival; MR, minor
response; PFS, progression free survival; PR, partial response; SC, subcutaneous; SD, stable disease; PD, progressive disease; SSA, somatostatin analogue; STZ, streptozotocin; TTP, time to progression; TTF, time-to-treatment
failure; QoL, quality of life; BID, twice daily; TID, three times daily; MU, milliunits.
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Study ﬂow
In total, 5,100 studies were identiﬁed from the literature search
(following removal of duplicates). A further fourteen relevant pub-
lications were identiﬁed from searching reference lists and confer-
ence proceedings. After excluding papers not meeting the inclusion
criteria, 52 publications of 47 studies were included in the system-
atic review (Fig. 1).Study characteristics
Systemic chemotherapy was the most common intervention
(two RCTs, 15 non-randomised studies) with many single-arm
studies evaluating a wide range of agents (Table 2). The second
most frequently reported treatments were SSAs and radiolabeled
SSA therapies (nine non-randomised studies), followed by
novel targeted agents (two RCTs and six non-randomised studies),
liver-directed therapies (six non-randomised studies), mixedTable 3
Survival/response data reported in RCT studies. Additional HRs are reported in footnotes.
Study reference Treatment Survival
Median PFS,
months (95% CI)
OS, HR
(95% CI)
Median
OS,
years
Targeted therapy (n = 2)
Raymond 2011
[33,35]
Sunitinib 11.4 (7.4–19.8) 0.74
(0.47–
1.17);
p = 0.19
30.5 mo
(20.6,
NR)
Placebo 5.5 (3.6–7.4)
HR 0.42 (0.26–
0.66);
p < 0.0001 vs.
placebo
24.4 mo
(16.3,
NR)
Yao 2011
RADIANT-3
[34]
Everolimus 11.0 (8.4–13.9) HR 0.89
(0.64-
1.23);
p = 0.59––
Not
reached
Placebo 4.6 (3.1–5.4)
HR 0.35 (0.27–
0.45);
p < 0.001§§§
36.6
mo
Chemotherapy (n = 2)
Moertel 1992 [28] Chlorozotocin NR N 1.5–
Streptozocin + Fluorouracil 1.4
Streptozocin + Doxorubicin 2.2
Moertel 1980 [27] Streptozocin NR NR 16.5 mo
Streptozocin + Fluorouracil 26 mo
Mixed treatments (n = 1)
Pavel 2008 [32] Streptozotocin/
Fluorouracil
NR NR NR
Octreotide
CI, conﬁdence interval; mo, months; NR, not reported; OS, overall survival; PFS, progres
 Investigator assessed.
 p = 0.007 vs. placebo.
§ Assessed using RECIST criteria.
– p < 0.03 vs. Streptozocin + Doxorubicin.
 p < 0.004 vs. Streptozocin + Doxorubicin.
 Response/regression deﬁnition used : Favourable objective response if tumour mass r
50% tumour regression.
§§ Median duration of response: ‘all responses’, 17 months; ‘complete responses’, 24 mo
–– OS Analysis cut-off Feb 2011 (146 events: 68 everolimus; 78 placebo). The result is co
OS not reached for everolimus treatment arm, so data immature [80]. No crossover adju
 (i) Investigator assessed PFS: revised HR based on excluding patients who had WHO
Raymond, 2011 study: 0.38 (0.29–0.49) [42]; (ii) Analysis of data for a subgroup of 84 p
review assessment: sunitinib, 19.8 months vs. placebo, 5.8 months: investigator assesse
review of the tumour imaging scans: sunitinib 12.6 months vs. placebo 5.8 months; HR
 Analysis conducted June 2010. The result is confounded by crossover; 69% of patien
models to adjust for crossover (median follow-up 34.1 months): (i) censoring at crosso
p = 0.01; (iii) RPSFT model, 0.43 (0.17–1.20); p = 0.12; (iv) RPSFT model adjusted for cro
§§§ Central review assessment of ﬁnal PFS: everolimus 11.4 months (10.8-14.8) vs. plactreatment regimens (one RCT, four non-randomised studies) and
other interventions such as interferon and recombinant human
endostatin (one non-randomised study each).
A summary of the included studies is reported in Table 2. The
included studies were highly varied in terms of study design; dura-
tion and outcomes; sample size; doses and schedules of the inter-
ventions employed (particularly in systemic chemotherapy
studies) and features of the enrolled patient populations. A signif-
icant proportion (15%) of the included studies were published over
15 years ago including two of the pivotal RCTs [27,28]. These early
studies often used criteria (e.g. physical examination) which are no
longer considered appropriate to measure response to treatment.
More recent studies have reported response rates using validated
radiological criteria such as WHO [29] and RECIST [30].Study quality
Two of the early conducted RCTs [27,28] had an open-label
study design and reported ambiguous allocation methods. Both
of these criteria have been reported to be important determinantsTumour response
Complete
response,
%
Partial
response,
%
Stable
disease,
%
Progressive
disease,
%
Any
response,
%
Objective
response
rate, %
Median
duration of
response,
months
2§ 7§ 63§ 14§ 9.3,§
0§ 0§ 60§ 27§ 0§
73 14
51 42
6 NR NR NR 30 NR 21
4 45 13
14 69 22
12 NR NR NR 36 NR NR§§
33 63
13 25 63 NR NR NR NR
0 13 75
sion-free survival; HR, hazard ratio.
educed by > 50% or 30% if malignant hepatomegaly was used, lab assay reduced by
nths.
nfounded by crossover, 85% of patients crossed from placebo to everolimus. Median
sted OS estimates have currently been published.
performance status of 2 from the RADIANT-3 trial (to match inclusion criteria of the
atients for whom MRI/CT scans were available to compare the results with central
d HR 0.45 HR 0.45 (0.22–0.92) [39]; (iii) Retrospective blinded independent central
0.32 (0.18–0.55) [49].
ts crossed from placebo to sunitinib. Additional HRs (95% CI) reported using four
ver, 0.43 (0.24–0.77); p = 0.004; (ii) time-dependent Cox model, 0.49 (0.29–0.85);
ssover time, 0.57 (0.18–1.09); p = 0.12 [48].
ebo 5.4 months (4.3-5.6); HR 0.34 (0.26–0.44) [34].
Table 4
Survival/response data reported in non-RCT studies.
Outcome Chemotherapy
(n = 15)
Mixed
treatments
(n = 4)
Targeted
therapy
(n = 6)
SSA/radionuclide
therapy (n = 9)
Liver directed
therapies (n = 6)
Interferon
(n = 1)
Recombinant
endostatin (n = 1)
Survival. No. of studies (no. PNET patients receiving the intervention)
No. studies reporting OS 2 (30) NR NR NR NR NR 1 (20)
Reported range in OS (%) 65–72 NR NR NR NR NR 17.2
No. studies reporting median
survival
7 (169) NR NR 1 (13) 3 (72) NR NR
Reported range in median survival
(months)
6–66 NR NR 23 9–40 NR NR
No. studies reporting 1-year
survival rate
NR NR 2 (226) NR NR NR NR
Reported range in 1-year survival
rate (%)
NR NR 75–81 NR NR NR NR
No. studies reporting median TTP NR NR NR NR 1 (46) NR NR
Reported range in median TTP
(months)
NR NR NR NR 4–22 NR NR
No. studies reporting median PFS 2 (30) 2 (65) 1 (160) 1 (21) NR NR 1 (20)
Reported range in median PFS
(months)
9.1-13 6-12 10–17 41 NR NR 5.8
Response No. of studies (no. PNET patients receiving the intervention)
No. studies reporting median
duration of response
5 (163) 1 (107) 1 (115) NR 3 (72) 1 (22) NR
Reported range in median duration
of response (months)
9–36 16–23 10.6 NR 3.6–24 8.5 NR
No. studies reporting any response NR NR NR NR 4 (57) 1 (22) NR
Reported range in no. of patients
with any response, %
NR NR NR NR 17–80 77 NR
No. studies reporting complete
response
13 (278) 3 (153) 6 (338) 5 (102) NR 1 (22) 1 (20)
Reported range in no. of patients
with complete response %
0–8 0 0 0–8 NR 5 0
No. studies reporting partial
response
13 (278) 3 (153) 6 (338) 6 (113) 1 1 (22) 1 (20)
Reported range in no. of patients
with partial response %
0–71 19–27 4–32 0–73 NR 5 0
No. studies reporting minor
response
NR NR NR 2 (63) NR NR NR
Reported range in no. of patients
with minor response %
NR NR NR 0–21 NR NR NR
No. studies reporting stable disease 11 (184) 3 (153) 4 (280) 7 (133) 1 NR NR
Reported range in no. of patients
with stable disease %
11–75 19–69 10–80 27–60 NR NR NR
OS, overall survival; TTP, time to progression; SSA, somatostatin analogue.
 2-year OS.
 Data not reported for subset of pNET patients (20/42).
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timate the treatment effect [31]. The mixed treatment RCT [32]
was reported as a conference abstract only and therefore limited
information on determinants of bias was reported. Two further
placebo-controlled RCTs examining the targeted therapies suniti-
nib [33] and everolimus [34] were powered to show standard
oncological end-points (PFS and OS) and employed the standard-
ised RECIST criteria to measure response.
Manyof thenon-randomisedstudiesenrolledsmallnumbersofpa-
tients and are therefore underpowered to detect signiﬁcant treatment
effects. Forty of the42non-randomised studies enrolled50patients or
less (median 19, [range 11–50] patients). The older studies tended to
lack standardised inclusion criteria (e.g. including heterogenous tu-
mour subtypes, patients with different exposure to prior therapy,
severity of disease or evidence of disease progression at study entry).
The majority of non-randomised studies reported partial infor-
mation making it difﬁcult to appraise study quality using the
Chambers checklist [26].
Efﬁcacy
A summary of the survival and response data reported in RCT
and non-randomised studies is reported in Tables 3 and 4respectively; given the higher level of evidence they provide we
will focus on the RCTs.
Chemotherapy was the subject of two early RCTs published in
1980 [27] and 1992 [28]. The ﬁrst study established that doublet
chemotherapy (streptozocin and 5-FU) resulted in a superior
response rate (63% vs. 36%) and OS (26 vs. 16.5 months) compared
with streptozocin monotherapy in 82 randomised patients [27]. In
the follow-on study comparing chlorozotocin vs. streptozocin/
doxorubicin vs. streptozocin/5-FU, patients receiving combination
chemotherapy once again fared better, with a response rate of
69% and OS of 2.2 years reported for the streptozocin/doxorubicin
combination which appeared to be the most active regimen,
although associated with signiﬁcant toxicity [28]. Chemotherapy
was adopted as the standard of care based on the results of these
two early RCTs [27,28].
The two most recent RCTs (assessing the targeted agents
sunitinib and everolimus), are the ﬁrst and only published studies
to documented an improvement in PFS compared with best
supportive care (BSC)/placebo. Both studies had a similar design:
selection of a homogeneous patient subgroup (pathologically-
conﬁrmed well-differentiated pNET with evidence of disease
progression), use of a double-blind placebo-controlled design using
a robust oncological end-point (PFS, by RECIST) and ability of
Table 5
Summary of safety data reported in RCT studies.
Study
reference
Treatment Treatment-
related
deaths, %
Withdrawals
due to AEs, %
Neutropenia, % Thrombocytopenia,
%
Nausea,
%
Vomiting,
%
Diarrhoea,
%
Stomatitis,
%
Targeted therapy (n = 2)
Raymond
2011
[33]
Sunitinib 1 17 All grade, 29
Grade 3/4, 12
All grade, 17
Grade 3/4, 4
All
grade,
45
Grade
3/4, 1
All grade,
34
Grade 3/4,
0
All grade,
59
Grade 3/4,
5
All grade,
22
Grade 3/4,
4
Placebo 1 8 All grade, 4
Grade 3/4, 0
All grade, 5
Grade 3/4, 0
All
grade,
29
Grade
3/4, 1
All grade,
30
Grade 3/4,
2
All grade,
39
Grade 3/4,
2
All grade, 2
Grade 3/4,
0
Yao 2011
[34]–––
Everolimus 2 17 NR All grade, 13
Grade 3/4, 4
All
grade,
20
Grade
3/4, 2
All grade,
15
Grade 3/4,
0
All grade,
34
Grade 3/4,
3
All grade,
64
Grade 3/4,
7
Placebo 1 3 NR All grade,<1
Grade 3/4, 0
All
grade,
18
Grade
3/4, 0
All grade,
6
Grade 3/4,
0
All grade,
10
Grade 3/4,
0
All grade,
17
Grade 3/4,
0
Chemotherapy (n = 2)
Moertel
1992
[28]
Chlorozotocin 0 NR Any§, 43
Severe–, 2
Any, 22
Severe, 6
NR Any, 43
Severe, 2
Any, 6
Severe, 0
Any, 0
Severe, 0
Streptozocin + Fluorouracil 3 Any§, 81
Severe–, 41
Any, 8
Severe, 6
Any, 81
Severe, 41
Any, 33
Severe, 2
Any, 19
Severe,
Streptozocin + Doxorubicin 0 Any§, 80
Severe–, 20
Any, 0
Severe, 0
Any, 80
Severe, 20
Any, 5
Severe, 0
Any, 5
Severe, 0
Moertel
1980
[27]
Streptozocin 5 4 Mild, 5%;
moderate§§, 0%;
severe––, 0%
Mild, 5%;
moderate, 0%;
severe§§§, 0%
Mild, 24%; moderate,
24%; severe, 36%
NR 0
Streptozocin + Fluorouracil 0 Mild, 52%;
moderate§§,
10%; severe––,
10%
Mild, 4%;
moderate, 12%;
severe§§§, 12%
Mild, 32%; moderate,
32%; severe, 22%
5
Mixed treatments (n = 1)
Pavel
2008
[32]
Streptozotocin/
Fluorouracil
NR NR Main AEs nausea, emesis, mucositis, electrolyte disturbance and thromboembolism
Octreotide Main AEs: abdominal pain and meteroism
 Thrombocytopenia: any,<100  109 cells/litre.
 Thrombocytopenia: severe:<50  109 cells/litre.
§ Leukopenia: any,<4  109 cells/litre.
– Leukopenia: severe:<2  109 cells/litre.
 Treatment group not reported.
 <4000 to P2000/mm3.
§§ <2000 to P1000/mm3.
–– <1000/mm3.
 <150,000 to P100,000/mm3.
 <100,000 to P50,000/mm3.
§§§ <50,000/mm3.
––– Extended follow up (20.1 months) [everolimus vs. placebo]: Diarrhoea, all grade: 34.3 vs. 10.3%; stomatitis, all grade: 52.9 vs. 12.3%; stomatitis, grade 3/4, 4.9% vs. 0%.
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progression. Sunitinib demonstrated an improved PFS of 11.4 vs.
5.5 months (vs. placebo, HR 0.42 (0.26–0.66); p < 0.0001 vs.
placebo) [33] and everolimus also had a similar magnitude of effect
with an improved PFS of 11.0 vs. 4.6 months (vs. placebo, HR 0.35
(0.27–0.45); p < 0.001) [34]. Although neither of the targeted
agents reported a signiﬁcantly improved OS compared with
placebo [33,34], this endpoint could not be reliably assessed due
to extensive crossover from placebo to active treatment (69% of
patients in the sunitinib trial and 74% of patients in the everolimus
trial) [34,35]. An exploratory analysis attempting to correct for
such patient crossover suggests an improved OS for sunitinib
compared with placebo [48].
The ﬁnal RCT (comparing streptozocin / 5-FU vs. octreotide) will
not be discussed further given its small size (n = 16 patients) and
the limited abstract-only available information.It was not possible to draw conclusions on the comparable efﬁ-
cacy of different interventions due to the signiﬁcant heterogeneity
between studies. There was signiﬁcant variation in the duration of
follow up between studies, which limits the assessment of survival
outcomes. The comparability of efﬁcacy between studies was also
hampered by differences in eligibility criteria, baseline characteris-
tics, and response criteria employed in these studies. For example,
differences in PFS between studies could be attributed to studies
not requiring disease progression or prior chemotherapy prior to
enrolment. The importance of response criteria is illustrated by
two RCTs which established streptozocin combined with either ﬂu-
orouracil or doxorubicin as the treatment of choice in pNET based
on ‘‘response rates’’ of 45–69%; however, these ‘‘responses’’ in-
cluded reduction in clinical hepatomegaly, biochemical improve-
ment and/or radiological regression [27,28]. Over the last
30 years, signiﬁcant advances in imaging techniques have resulted
Table 6
Summary of safety data reported in non-RCT studies.
Study reference Targeted
therapy
(n = 6)
Chemotherapy
(n = 15)
Mixed
treatments
(n = 4)
SSA/radionuclide
therapy (n = 9)
Liver directed
therapies (n = 6)
Interferon
(n = 1)
Endostatin
(n = 1)
Incidence of withdrawals: no. of studies
(enrolled patients)
NR 1 (29) NR 1 (15) NR NR NR
Incidence of withdrawals: range, % – 100 – 13 – –
Incidence of treatment-related deaths: no.
of studies (enrolled patients)
1 (15) NR NR NR 1 NR NR
Incidence of treatment-related deaths:
range, %
7 – – – – – –
Incidence of AEs: no. of studies (enrolled
patients)
NR NR 1 (35) NR NR NR NR
Incidence of AEs: range, % – – – – – – –
Incidence of SAEs: no. of studies (enrolled
patients)
NR 1 NR 1 (27) NR NR NR
Incidence of SAEs: range, % – 8 – 0 – – –
Incidence of neutropenia: no. of studies
(enrolled patients)
1 (160) 4 (148) NR NR NR 1 (22) NR
Grade 1-2 neutropenia: range, % 6 51-16 – – – 66 –
Grade 3–4 neutropenia: range, % 3 23–64 – – –
Incidence of thrombocytopenia: no. of
studies (enrolled patients)
3 (182) 1 (51) 1 (30) NR NR 1 (22) NR
Grade 1–2 thrombocytopenia: range, % 5–50 14 – – – 38– –
Grade 3–4 thrombocytopenia: range, % 3–17 22 5% – – – –
Incidence of nausea: no. of studies
(enrolled patients)
2 (175) 4 (86) 2 (46) NR NR NR NR
Grade 1–2 nausea: range, % 30–36 8–21 13 – – – –
Grade 3–4 nausea: range, % 0–1 3–13 2 – – – –
Incidence of diarrhoea: no. of studies
(enrolled patients)
2 (54) 6 (221) 2 (46) NR NR NR NR
Grade 1–2 diarrhoea: range, % 30 5–12 18 – – – –
Grade 3–4 diarrhoea: range, % 5–9 0–13 11 – – – –
Incidence of vomiting: no. of studies
(enrolled patients)
1 (150) 4 (126) NR NR NR NR NR
Grade 1–2 vomiting: range, % 16 38–71 – – – – –
Grade 3–4 vomiting: range, % 0 3–14 – – – – –
Incidence of fatigue: no. of studies
(enrolled patients)
3 (95) 1 (29) 2 (65) NR NR NR NR
Grade 1–2 fatigue: range, % 78 76 – – – – –
Grade 3–4 fatigue: range, % 0–9 7 9––11 – – – –
Incidence of hypertriglyceridaemia: no. of
studies (enrolled patients)
2 (32) NR 1 (30) NR NR 1 (22) NR
Grade 1–2 hypertriglyceridaemia: range, % 42 – 44 – – 33§ –
Grade 3–4 hypertriglyceridaemia: range, % 3–6 – 3 – – – –
Incidence of rash: no. of studies (enrolled
patients)
4 (231) 1 (29) 1 (30) NR NR NR NR
Grade 1–2 rash: range, % 41–61 35 – – – – –
Grade 3–4 rash: range, % 1–6 3 5 – – – –
Incidence of pneumonitis: no. of studies
(enrolled patients)
2 (175) NR NR NR NR NR NR
Grade 1–2 pneumonitis: range, % 8–19 NR – – – – –
Grade 3–4 pneumonitis: range, % 0 NR – – – – –
Incidence of hypertension: no. of studies
(enrolled patients)
NR NR 2 (65) NR NR NR NR
Grade 1–2 hypertension: range, % – – – – – – –
Grade 3–4 hypertension: range, % – – 2–12 – – – –
 AE data not reported for the subset of patients (20/42) with pNET.
 Leukocyte count <4.0  109/l: grade not explicitly reported.
§ Rise in serum triglycerides: grade not explicitly reported.
– Platelet count fall to <150  109/l: grade not explicitly reported.
 All patients were alive at time of publication of the abstract.
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teria to describe tumour response such as the WHO criteria or,
more recently, RECIST. Several subsequent studies, using these
stricter radiological deﬁnitions of response rather than clinical
ones, have, however failed to conﬁrm the high response rates seen
in the early RCTs [27,28].Health related quality of life (HRQoL)
Despite the increasing importance of patient reported outcomes
(PRO) in assessing the effectiveness of treatments, HRQoL has been
rarely assessed in this patient population. Indeed, only two studies,
both investigating the targeted therapy sunitinib, assessed QoL
using validated PROmeasures (EORTC Quality of Life Questionnaire
N
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Fig. 2. Relationship between date of publication and number of patients enrolled in clinical studies.
386 J.W. Valle et al. / Cancer Treatment Reviews 40 (2014) 376–389[33] and EQ-5D/FACIT Questionnaire [36], in the absence of a NET-
speciﬁc quality of life tool). In both studies, despite its inherent
toxicities, active treatment did not result in signiﬁcant detriment
from baseline in overall QoL measures compared with best sup-
portive care.Safety
A summary of selected AEs are reported in Table 5 (RCTs) and
Table 6 (non-randomised studies). In general, the reported inci-
dence of grade 3–4 AEs was similar to the previously characterised
proﬁle for the different classes of agents. Chemotherapy agents
have high levels of reversible myelosuppression, emesis (especially
prior to the use of modern anti-emetics) and agent-speciﬁc toxici-
ties (e.g. doxorubicin-induced cardiotoxicity; ﬂuoropyrimidine-in-
duced diarrhea). The targeted therapies (sunitinib and everolimus)
have fewer grade 3–4 toxicities compared with chemotherapeutic
agents in keeping with experience of these drugs in other tumour
types.Discussion
This systematic review was undertaken to assess non-surgical
treatments for pNET. Robust methods were used to identify all rel-
evant studies and assess the methodological quality of the in-
cluded studies.
RCTs represent the gold standard study design for assessment of
treatment efﬁcacy. However, there are few RCTs performed to date
to assess the efﬁcacy and tolerability of treatment options in the
management of pNET. This is partly due to the complexity and clin-
ical heterogeneity of pNETs and a perception that these tumourswere ‘‘too rare’’ to undertake adequately-powered RCTs. As a re-
sult, most of the published evidence base comes from single-arm
non-randomised studies. While recently conducted non-random-
ised studies have employed validated criteria to measure patient
response [36–38], many older ‘historical’ studies lacked standard-
ised inclusion criteria (e.g. including heterogenous tumour sub-
types, and patients with varied severity of disease, extent of prior
therapy, evidence of disease progression at study entry and other
prognostic factors) and standardised outcomes [22] are were not
adequately powered to provide robust information on treatment
responses and survival [40,41]. Fig. 2 indicates that over the last
three decades, while studies examining chemotherapy regimens
have continued to enrol a consistently small number of patients
(<50 patients), the last ﬁve years has seen the publication of ade-
quately powered studies (both observational and RCTs) examining
targeted therapies enrolling a larger number of patients. Such stud-
ies are both sufﬁciently powered and report clinically meaningful
endpoints such as PFS and OS and have indicated the feasibility
of conducting robust RCTs.
There are currently no head-to-head RCTs comparing the efﬁ-
cacy of licensed treatments in this indication in the ﬁrst-line set-
ting or studies evaluating the optimal sequencing of available
therapies.
Results from the present review indicate that over the last three
decades, the criteria used to address response in pNET have pro-
gressed from clinical / biological responses to the use of validated
WHO and RECIST criteria. However, these criteria have been vali-
dated for cytotoxic chemotherapy. As the use of targeted agents in-
creases, patients may beneﬁt from novel criteria (e.g. Choi) which
assess both tumour density/necrosis in addition to change in tu-
mour size. Targeted therapies can induce extensive regions of
necrosis within a tumour. Although the induction of tumour necro-
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stricted to measuring tumour size and so unlike the Choi criteria,
they are insensitive to changes in tumour density and may there-
fore underestimate the anti-tumour effect of targeted agents in
pNET, which are generally insidious in nature. While the utility
of the Choi criteria have been established in the management of
gastrointestinal stromal tumours (GIST) [43], ongoing studies will
report on their sensitivity and precision in assessing the response
of pNET to targeted therapies [44–46].
Despite the limitations in the robustness of its data, systemic
cytotoxic chemotherapy has a role in the management of pNET; in-
deed it is recommended as a ﬁrst-line treatment option by the
European Neuroendocrine Tumour Society [9]. However, there is
scope for improved, robust evidence of its efﬁcacy from future
RCTs.
Several new targeted agents have been developed and investi-
gated in recent studies although again the majority of these have
been assessed in non-randomised studies (Table 2). This review
identiﬁed two RCTs assessing targeted therapies: one examining
sunitinib [33] and one everolimus [34]. Based on these results,
these agents are valid and applicable treatment options for pa-
tients with advanced pNET in daily practice. However, there re-
main as yet a number of unexplored issues such as the optimal
positioning of these drugs with respect to each other and, indeed,
chemotherapy; the feasibility, safety and efﬁcacy of combining
these treatments with other modalities (e.g. liver-directed therapy,
or radionuclide therapy); as well as their role in other stages of the
disease pathway (e.g. neoadjuvant or as an adjuvant therapy to
surgery) [47].
Furthermore, the concept of personalised patient-speciﬁc treat-
ment depending on tumour histology, comorbid conditions and
objectives of treatment as part of an optimised treatment algo-
rithm is becoming increasingly important [41]. For example, pa-
tients with a high tumour burden or mitotically active tumour
(as measured by Ki67 index) may beneﬁt from an antiproliferative
treatment such as chemotherapy. However, for those patients with
low-grade tumours or lower tumour burden, consideration of the
patient’s quality of life is of utmost importance. In such cases, re-
sults from the phase III sunitinib RCT indicate that clinical beneﬁts
were gained without adversely affecting quality of life [33].
Whilst the majority of published evidence comes from non-ran-
domised studies, the two recently published studies [33,34] assess-
ing the targeted therapies have indicated the feasibility of
conducting robust trials which report clinically meaningful end-
points such as PFS and OS. Following publication of the sunitinib
trial, the United States Food and Drug Administration (FDA) has is-
sued a recommendation that interim efﬁcacy analyses should be
carefully planned in order to reduce the risk of overestimating
treatment effects [35]. Further research will be required to conﬁrm
the efﬁcacy of these novel therapies and to deﬁne the ideal treat-
ment algorithm for the management of pNET. These trials will re-
quire international collaboration and should ideally be designed
following multidisciplinary clinical input and include patients clas-
siﬁed according to histological guidelines speciﬁcally developed for
pNETs to ensure homogenous enrolment of patients. In addition,
future trials should assess alternative treatment strategies incorpo-
rating effective agents, used concurrently or sequentially depen-
dent on tumour characteristics, which may replace the concept
of a single therapy per patient.Conﬂict of interest statement
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